University of Patras
Διερεύνηση των μηχανισμών ευαισθησίας / αντοχής στους αναστολείς πρωτεασώματος των μυελωματικών κυττάρων ασθενών με πολλαπλούν μυέλωμα
Abstract
dc:descriptionMultiple Myeloma (MS) accounts for 10% of all the hematological neoplasms and is characterized by the abnormal proliferation and maturation of plasma cells in the bone marrow, leading more commonly to osteolytic bone lesions, hypercalcemia, renal failure and anemia. and less frequently to various other clinical manifestations. Despite recent advances in the treatment of myeloma with proteosome inhibitors (PIs), immunomodulatory drugs, monoclonal antibodies and other classes of agents, many patients ultimately develop resistance to treatment, resulting in relapse, which shares poor clinical course and dismal prognosis. The mechanisms underlying PIs’ resistance are not fully understood, while data suggest the development of complex interactions between the cell's proteolytic systems and oxidative stress. To this end, the dynamic relationship between the ubiquitin-proteasome system (UPS), autophagy, and oxidative stress in MM progression and PI resistance was investigated. Bone marrow samples from MM patients at various time points of disease course (baseline, remission, and relapse) and from control subjects, without bone marrow infiltration by any type of neoplastic cells were analyzed. The proteolytic activity of the proteasome, expression levels of the β5 proteasomal e subunit (PSMB5), autophagy marker LC3II, and intracellular reactive oxygen species expression levels (ROS) were assessed, using a combination of biochemical assays, Western blotting, and flow cytometry. Additionally, in vitro experiments were conducted, using cell lines to further elucidate the mechanisms of interaction between these systems. The results show that PSMB5 accumulation was significantly reduced after PI treatment, with a similar pattern observed in proteasome proteolytic activity (PPA). Conversely, LC3II protein levels were significantly elevated, at both, remission and relapse phase, compared to baseline levels, indicating enhanced autophagy activation, following PI treatment. A statistically significant negative correlation between PSMB5 and LC3II expression was identified across all disease phases, suggesting a reciprocal association between these two major cellular proteolytic systems. Median ROS levels were significantly higher at relapse, compared to both, baseline and remission levels, and were negatively correlated with PPA, and positively with autophagy activation. Longitudinal analysis of same patients’ samples demonstrated that changes in PSMB5 and LC3II levels exhibited an inverse association during disease progression and treatment, further supporting the compensatory relationship between the UPS and autophagy. In vitro experiments confirmed these findings, with autophagy inhibition using Wortmannin significantly inducing PSMB5 expression. Furthermore, the study identified PSMB5 expression levels as a promising prognostic marker of relapse, after treatment with PIs and suggests that the activation of autophagy serves as an adaptive/counteracting mechanism, contributing to PIs resistance. These findings may have important clinical implications, indicating that combined therapeutic approaches, targeting both proteolytic pathways may overcome resistance and improve treatment outcomes in MM patients. Furthermore, integrating the assessment of PSMB5, autophagy markers, and oxidative stress parameters into patient evaluation could provide valuable tools for predicting treatment response and optimizing personalized therapeutic strategies in MM
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Plakoula, Eva
- Πλακούλα, Εύα
Subjects
dc:subject × 16- Πολλαπλό μυέλωμα
- Πρωτεάσωμα
- Αναστολείς πρωτεασώματος
- Αυτοφαγία
- Οξειδωτικό στρες
- Multiple myeloma
- Proteasome
- Proteasome inhibitors
- Autophagy
- Oxidative stress
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59418